Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267777 | 1.00 | TRPA1 (0.31) | TRPA1TRPM8KCNH2GBA1 | |
| SCHEMBL21744770 | 1.00 | TRPA1 (0.31) | TRPA1TRPM8KCNH2GBA1 | |
| SCHEMBL24267942 | 1.00 | TRPA1 (0.31) | TRPA1TRPM8KCNH2GBA1 | |
| SCHEMBL25091193 | 1.00 | TRPA1 (0.31) | TRPA1TRPM8KCNH2GBA1 | |
| SCHEMBL9920196 | 1.00 | TRPA1 (0.31) | TRPA1TRPM8KCNH2GBA1 | |
| SCHEMBL29299542 | 0.86 | SLC6A1 (0.33) | — | |
| SCHEMBL18523966 | 0.83 | TRPA1 (0.32) | TRPA1TRPM8 | |
| SCHEMBL20676098 | 0.81 | TRPA1 (0.31) | TRPA1TRPM8KCNH2 | |
| SCHEMBL19122839 | 0.81 | TRPA1 (0.31) | TRPA1TRPM8KCNH2 | |
| SCHEMBL18309924 | 0.81 | TRPA1 (0.31) | TRPA1TRPM8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | TRPA1 4678/4885TRPM8 2429/4885KCNH2 3823/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | TRPA1 4678/4885TRPM8 2429/4885KCNH2 3823/4885 |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | TRPA1 3630/4885TRPM8 1642/4885KCNH2 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.